Edition:
United States

Idera Pharmaceuticals Inc (IDRA.OQ)

IDRA.OQ on NASDAQ Stock Exchange Capital Market

2.38USD
12:21pm EDT
Change (% chg)

$-0.10 (-4.03%)
Prev Close
$2.48
Open
$2.45
Day's High
$2.49
Day's Low
$2.30
Volume
80,319
Avg. Vol
102,950
52-wk High
$4.42
52-wk Low
$1.20

Summary

Name Age Since Current Position

James Geraghty

60 2013 Independent Chairman of the Board

Vincent Milano

51 2014 President, Chief Executive Officer, Director

Youssef El Zein

66 1997 Independent Vice Chairman of the Board

Louis Arcudi

54 2011 Chief Financial Officer, Senior Vice President - Operations, Treasurer, Secretary

Robert Fletcher

52 2015 Senior Vice President - Business Development and Strategic Planning

Joanna Horobin

60 2015 Senior Vice President, Chief Medical Officer

Robert Doody

2014 Vice President - Investor Relations and Corporate Communications

William Reardon

69 2010 Lead Independent Director

Sudhir Agrawal

61 2014 Director, President of Research

Maxine Gowen

57 2016 Director

Julian Baker

50 2014 Independent Director

Mark Goldberg

61 2014 Independent Director

Kelvin Neu

41 2014 Independent Director

Eve Slater

69 2010 Independent Director

Biographies

Name Description

James Geraghty

Mr. James A. Geraghty has been appointed as Independent Chairman of the Board of Idera Pharmaceuticals, Inc., effective July 8, 2013. He has been an Entrepreneur in Residence at Third Rock Ventures since May 2013. Mr. Geraghty served as a Senior Vice President of Sanofi from April 2011 to December 2012. Prior to that, he served in various senior management roles at Genzyme Corporation, a biotechnology company, from 1992 to April 2011, including as Senior Vice President, International Development from January 2007 to April 2011. He previously served as a director of bluebird bio Inc. and GTC Biotherapeutics, Inc. We believe that Mr. Geraghty’s qualifications to sit on our board of directors include his public company board and management experience and his broad and deep knowledge of the industry in which we operate.

Vincent Milano

Mr. Vincent J. Milano is President, Chief Executive Officer, Director of Idera Pharmaceuticals, Inc., effective December 1, 2014, Prior to joining us, Mr. Milano served as Chairman, President and Chief Executive Officer of ViroPharma Inc., which was acquired by Shire Plc in January 2014, from March 2008 to January 2014, as its Vice President, Chief Financial Officer and Chief Operating Officer from January 2006 to March 2008 and as its Vice President, Chief Financial Officer and Treasurer from April 1996 to December 2005. Mr. Milano also served on the board of directors of ViroPharma from March 2008 to January 2014. Prior to joining ViroPharma, Mr. Milano served in increasingly senior roles, most recently senior manager, at KPMG LLP, an independent registered public accounting firm, from July 1985 to March 1996. Mr. Milano currently serves on the board of directors of Spark Therapeutics, Inc. and Vanda Pharmaceuticals Inc., each a publicly traded company, and VenatoRx Pharmaceuticals, Inc. Mr. Milano holds a Bachelor of Science degree in Accounting from Rider College. We believe Mr. Milano’s qualifications to sit on our board of directors include his knowledge of our company as our President and Chief Executive Officer, knowledge of our industry, including over 18 years of experience serving in a variety of roles of increasing responsibility in the finance department, corporate administration and operations of a multinational biopharmaceutical company, and understanding of pharmaceutical research and development, sales and marketing, strategy, and operations in both the United States and overseas. He also has corporate governance experience through service on other public company boards.

Youssef El Zein

Mr. Youssef El Zein is an Independent Vice Chairman of the Board of Idera Pharmaceuticals, Inc. He has been the Managing Partner of Pillar Invest Corporation, a Cayman Island company that he founded, and the General Partner of a family of funds, including Pillar Pharmaceuticals I, L.P. and Pillar Pharmaceuticals II, L.P., since 2011. Mr. El Zein has been the chairman and Chief Executive Officer of Pillar Invest (offshore) SAL since 2009. Mr. El Zein has been managing partner of Pillar Investment Limited, a private investment firm, since 1991.

Louis Arcudi

Mr. Louis J. Arcudi,III., is Chief Financial Officer, Senior Vice President - Operations, Treasurer, Secretary of Idera Pharmaceuticals, Inc. Prior to joining us, Mr. Arcudi served as Vice President of Finance and Administration and Treasurer for Peptimmune, Inc., a biotechnology company, from 2003 to 2007. From 2000 to 2003, Mr. Arcudi was Senior Director of Finance and Administration at Genzyme Molecular Oncology Corporation, a division of Genzyme Corporation. He was Director of Finance Business Planning and Operations International at Genzyme from 1998 to 2000. Prior to joining Genzyme, he held finance positions with increasing levels of responsibility at Cognex Corporation, a supplier of machine vision systems, Millipore Corporation, a provider of technologies, tools and services for bioscience, research and biopharmaceutical manufacturing, and General Motors Corporation, an automobile manufacturer.

Robert Fletcher

Mr. Robert Clayton Fletcher is Senior Vice President - Business Development and Strategic Planning of the Company. Mr. Fletcher served in increasingly senior positions at ViroPharma Inc., which was acquired by Shire Plc in January 2014, from April 2001 until January 2014, including as Vice President, Business Development and Project Management from 2005 until January 2014. Mr. Fletcher served as Senior Project Manager at SmithKline Beecham plc, a pharmaceutical company, which was purchased by Glaxo Wellcome plc in December 2000, from 1997 until 2001. Prior to working at SmithKline Beecham, he served as Project Scientist, at Becton, Dickinson and Company, a medical devices company and as Principal Scientist at Intracel Corporation, a biopharmaceutical company. Prior to working at Intracel, he served as Senior Associate Scientist at Centocor Biotech, Inc., a biotechnology company from 1991 until 1993.

Joanna Horobin

Dr. Joanna C. Horobin, M.D. is Senior Vice President, Chief Medical Officer of Idera Pharmaceuticals, Inc. Dr. Horobin has over 30 years of successful pharmaceutical development experience. Prior to her positions at Verastem and Syndax, she held several roles of increasing responsibility at global pharmaceutical corporations such as Rhône-Poulenc Rorer (now Sanofi) where she spearheaded the global Oncology business unit's launch which included the launches of Taxotere ® (docetaxel) in breast cancer and Campto/Camptosar ® (CPT11) for colorectal cancer. Dr. Horobin also led a successful joint venture with Chugai to launch Granocyte ® (lenograstim). Prior, Dr. Horobin played significant leadership roles in the approvals of Lovenox ® , Celectol ® , Augmentin ® , Timentin ® , temocillin, Bactroban ® and Relafen ® /Reliflex ® . Dr. Horobin received her medical degree from the University of Manchester, England.

Robert Doody

Mr. Robert A. Doody Jr. is Vice President - Investor Relations and Corporate Communications of the Company. Mr. Doody, most recently served for the past eight years as Head of Investor Relations of ViroPharma, which was acquired by Shire Pharmaceuticals in January 2014. During his tenure at ViroPharma the company transformed to a leading developer of innovative therapies for rare diseases, highlighted by its lead product, Cinryze, for the treatment of hereditary angioedema in the United States and Europe. Prior to joining ViroPharma, Mr. Doody spent several years at the healthcare communications firm, Dorland Sweeney Jones in Philadelphia. He received his Bachelor of Arts degree in Communications from Rowan University. Mr. Doody also served honorably in the United States Navy.

William Reardon

Mr. William S. Reardon,CPA., is Lead Independent Director of Idera Pharmaceuticals, Inc., since September 2010. He is a director since 2002. He served as an audit partner at PricewaterhouseCoopers LLP, where he led the Life Science Industry Practice for New England and the Eastern United States from 1986 until his retirement from the firm in July 2002. Mr. Reardon currently serves as a director of Synta Pharmaceuticals, Inc., a publicly traded company. Mr. Reardon has also served as a trustee of closed-end mutual funds H&Q Healthcare Investors and H&Q Life Sciences Investors since April 2010. We believe that Mr. Reardon’s qualifications to sit on our board of directors include his accounting and financial experience, including as a partner at a leading accounting firm leading its life science practice, his role in keeping the board of directors and senior management team abreast of current accounting regulations and his experience as a member of several boards of directors of biotechnology companies. Additionally, we value Mr. Reardon’s role in leading the board on matters of corporate governance, before, during and after his service as lead independent director.

Sudhir Agrawal

Dr. Sudhir Agrawal,D. Phill., is Director, President of Research of Idera Pharmaceuticals, Inc., effective December 1, 2014. He served as the chairman of our board of directors from September 2010 until July 2013. He also served as our Chief Scientific Officer from January 1993 until September 2010 and as Acting Chief Executive Officer from February 2000 until September 2001. Dr. Agrawal joined us in 1990 and served in various capacities before his appointment as Chief Scientific Officer, including Scientific Founder, Vice President of Discovery and Senior Vice President of Discovery. Prior to joining us, Dr. Agrawal served as a Foundation Scholar at the Worcester Foundation for Experimental Biology in Massachusetts, and conducted post-doctoral research at the Medical Research Council’s Laboratory of Molecular Biology in Cambridge, England and obtained his D. Phil from Allahabad University in India. We believe that Dr. Agrawal’s qualifications to sit on our board of directors include his unique insights into our challenges, opportunities and operations that he has as a result of the various roles he has played with us since our founding, including Scientific Founder, Chief Scientific Officer, Chief Executive Officer, Chairman and President of Research.

Maxine Gowen

Dr. Maxine Gowen Ph.D. is Director of the Company. Dr. Gowen is the founding President and Chief Executive Officer of Trevena, Inc. Prior to leading Trevena, Dr. Gowen held a variety of leadership roles at GlaxoSmithKline (GSK) over a period of fifteen years. Dr. Gowen also held a tenured academic position in the School of Pharmacology, University of Bath, UK. Dr. Gowen earned her Bachelor's degree in Biochemistry from the University of Bristol, UK, her Ph.D. in Cell Biology from the University of Sheffield, UK and earned her MBA from the Wharton School of the University of Pennsylvania. Dr. Gowen also serves on the Board of Directors of Akebia Therapeutics and the state and national biotechnology industry associations, PA BIO and BIO.

Julian Baker

Mr. Julian C. Baker is Independent Director of Idera Pharmaceuticals, Inc. Mr. Baker’s career as a fund manager began in 1994 when he co-founded a biotechnology investing partnership with his brother and the Tisch Family. Previously, Mr. Baker was employed from 1988 to 1993 by the private equity investment arm of Credit Suisse First Boston Corporation. He also serves on the boards of directors of Incyte Corporation and Genomic Health, Inc. and previously served on the board of directors of Trimeris, Inc. Mr. Baker holds an A.B. from Harvard University. We believe that Mr. Baker’s qualifications to sit on our board of directors include his financial expertise, affiliation with one of our significant stockholders, knowledge of our industry and significant public company board experience.

Mark Goldberg

Dr. Mark Goldberg, M.D., is Independent Director of the Company. He has served as Senior Vice President for Medical and Regulatory Affairs at Synageva BioPharma since September 2011. Before joining Synageva, he served in management capacities of increasing responsibility at Genzyme from 1996 to 2011, including most recently as Senior Vice President for Clinical Development and Global Therapeutic Group Head for Oncology and Personalized Genetic Health. While at Genzyme, Dr. Goldberg played a key role in the development and approval of four successful orphan therapies: Fabrazyme®, Aldurazyme®, Myozyme® and Lumizyme®. Prior to joining Genzyme, he was a full-time staff physician at Brigham and Women’s Hospital and the Dana-Farber Cancer Institute, where he still holds appointments. Dr. Goldberg is a board-certified medical oncologist and hematologist and has published more than 50 papers.

Kelvin Neu

Dr. Kelvin Neu is Independent Director of Idera Pharmaceuticals, Inc. The firm primarily manages long-term investment funds focused on publicly traded life sciences companies. Dr. Neu currently serves on the board of directors of XOMA Corporation, a publicly traded company. Dr. Neu also served as a director of AnorMED Inc. and diaDexus, Inc. Dr. Neu holds an A.B. in Molecular Biology from Princeton University and an M.D. from Harvard Medical School and the Harvard-MIT Division of Health Sciences and Technology. He also trained for three years in the Immunology Ph.D. program at Stanford University. We believe that Dr. Neu’s qualifications to sit on our board of directors include his scientific background, affiliation with one of our significant stockholders and knowledge of our industry.

Eve Slater

Dr. Eve E. Slater,M.D., is Independent Director of Idera Pharmaceuticals, Inc., since 2010. She is currently Professor of Clinical Medicine at Columbia University College of Physicians and Surgeons, where she has taught in various positions since 1983. Dr. Slater was Senior Vice President, Worldwide Policy at Pfizer, Inc. from May 2007 until June 2009. Dr. Slater was the Assistant Secretary for Health, United States Department of Health and Human Services from 2002 until 2003, and was the Acting Assistant Secretary for Health from 2001 until her confirmation by the United States Senate in 2002. Dr. Slater held senior management positions at Merck Research Laboratories from 1983 to 2001, including Senior Vice President of External Policy, Vice President of Corporate Public Affairs, Senior Vice President of Clinical and Regulatory Development, Executive Director of Biochemistry and Molecular Biology, and Senior Director of Biochemical Endocrinology. Dr. Slater was trained in Internal Medicine and Cardiology at Massachusetts General Hospital, is board certified in Internal Medicine and Cardiology and is a Fellow of the American College of Cardiology. We believe that Dr. Slater’s qualifications to sit on our board of directors include her extensive scientific and medical background, significant public company board experience, and years of service with pharmaceutical companies and governmental institutions.